Nabriva Therapeutics plc
NBRV
Rank in Stocks
#39899
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Share Price
$0.63
Last synced: 2023-08-29
Market Cap
$284.20K
Change (1 day)
-21.25%
Change (1 year)
629,900.02%
Country
IE
Trade Nabriva Therapeutics plc (NBRV)
Category
Healthcare
Stock price history for Nabriva Therapeutics plc (NBRV)
Highest end of day price: $0.00 on 2026-10-01
Lowest end of day price: $0.74 on 2023-08-01
Lowest end of day price: $0.74 on 2023-08-01
Stock price history of Nabriva Therapeutics plc from 2023 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | 60.55% |
| 2024 | 9.75% |
| 2023 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.08 | -4.30% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
